AML clones driven primarily by mutant FLT3 require a therapeutic agent that sustains near-complete inhibition of the FLT3 enzymatic activity and suppresses bypass pathways that can sustain prosurvival signaling even in the absence of FLT3 activity. Here, FLT3 is linked to acute myeloid leukemia.